Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...
Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia.
Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease progression.
ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...
ALS impacts tens of thousands of people across the United States, and hundreds in Arizona. There's research being done in the Valley that can hopefully help contribute to ending ALS.
QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...
Despite its increasing prevalence, a painful condition called bladder pain syndrome, or interstitial cystitis, remains ...
Elevated levels of p-tau 181 and 217 in cerebrospinal fluid are considered to reflect early Alzheimer's disease pathology.
Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback